APRE
Aprea Therapeutics, Inc.Company Information
- Company Name
- Aprea Therapeutics, Inc.
- CIK
- CIK0001781983
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- APRE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- APRE
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-01-30
- Last sale
- 2024-10-18
- Shares purchased (TTM)
- 65,759
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,370,855
- Shares outstanding
- 53,483,504
- Ownership
- 4.43%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 16.25%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 41 | 46 | 15 | 14 | 17 | 19 | 23 | 26 | 29 | 32 | 22 | 25 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | ||||||
| Assets Current | 42 | 47 | 16 | 14 | 17 | 20 | 24 | 26 | 30 | 33 | 23 | 26 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Assets | 42 | 48 | 16 | 14 | 17 | 20 | 24 | 27 | 30 | 33 | 23 | 26 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | ||||||
| Deferred Revenue Current | - | - | - | - | - | - | - | - | 0 | 0 | 1 | - | ||||||
| Liabilities Current | 3 | 5 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 4 | 4 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 390 | 390 | 357 | 353 | 352 | 351 | 351 | 351 | 351 | 350 | 336 | 336 | ||||||
| Common Stock Share Subscribed But Unissued Subscriptions Receivable | - | -0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -11 | -11 | -11 | -11 | -11 | -11 | -11 | -11 | -11 | -11 | -11 | -11 | ||||||
| Retained Earnings Accumulated Deficit | -341 | -337 | -334 | -331 | -328 | -325 | -321 | -318 | -314 | -311 | -308 | -305 | ||||||
| Stockholders Equity | 38 | 42 | 12 | 11 | 13 | 16 | 19 | 22 | 26 | 29 | 17 | 20 | ||||||
| Liabilities And Stockholders Equity | 42 | 48 | 16 | 14 | 17 | 20 | 24 | 27 | 30 | 33 | 23 | 26 | ||||||
| Convertible Preferred Stock Seriesa | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | ||||||
| Common Stock Shares Issued | 12 | 12 | 8 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 4 | ||||||
| Shares Outstanding | 12 | 12 | 8 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAprea Therapeutics, Inc. (APRE) — SEC Financial Statements & Analysis
Aprea Therapeutics, Inc. (APRE) is a pharmaceutical preparations company, incorporated in DE. Aprea Therapeutics, Inc. trades on Nasdaq as: APRE. Aprea Therapeutics, Inc. (APRE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Aprea Therapeutics, Inc. carries a market cap of $42.89M, a P/E ratio of -3.49x, a P/B ratio of 1.11x, an enterprise value of $1.62M, and an EV/EBITDA multiple of -0.12x. On profitability, it posts a Return on Equity (ROE) of -47.44% and a Return on Assets (ROA) of -41.30%. Per share, it reports EPS of $-0.23, diluted EPS of $-0.23, free cash flow per share of $-0.23, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -11.14% year-over-year and EPS growth of -89.89% year-over-year. On the balance sheet, it maintains a current ratio of 13.55x, a quick ratio of 13.33x, working capital of $38.82M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.07, an interest coverage ratio of -17.33x, free cash flow of $-12.18M (TTM), and net debt of $-41.28M. Figures sourced from SEC EDGAR.
- Market Cap
- $42.89M
- P/E TTM
- -3.49x
- EPS TTM
- $-0.23
- P/B TTM
- 1.11x
- ROE TTM
- -47.44%
- ROA TTM
- -41.30%
- Debt To Equity
- 0.08x
- Free Cash Flow TTM
- $-12.18M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aprea Therapeutics, Inc. in?
Aprea Therapeutics, Inc. (APRE) operates in the Pharmaceutical Preparations industry.
What exchange does APRE trade on?
Aprea Therapeutics, Inc. (APRE) trades on the Nasdaq.
Where is Aprea Therapeutics, Inc. incorporated?
Aprea Therapeutics, Inc. is incorporated in DE.
When was Aprea Therapeutics, Inc. (APRE)'s most recent SEC filing?
Aprea Therapeutics, Inc. (APRE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is APRE's market cap?
Aprea Therapeutics, Inc. (APRE) has a market capitalization of $42.89M as of 2026-06-30.
What is APRE's EPS (earnings per share)?
Aprea Therapeutics, Inc. (APRE)'s trailing twelve month EPS is $-0.23 as of 2026-06-30.
What is APRE's ROE (return on equity)?
Aprea Therapeutics, Inc. (APRE)'s trailing twelve month Return on Equity (ROE) is -47.44% as of 2026-06-30.
What is APRE's ROA (return on assets)?
Aprea Therapeutics, Inc. (APRE)'s trailing twelve month Return on Assets (ROA) is -41.30% as of 2026-06-30.
What is APRE's EV/EBITDA?
Aprea Therapeutics, Inc. (APRE)'s trailing twelve month EV/EBITDA is -0.12x as of 2026-06-30.